BRIDGET Study: Tucatinib Plus HER2-Directed Antibody Therapy in Breast Cancer

Opinion
Video

An overview of the design and rationale for the phase 2 BRIDGET study looking at the addition of tucatinib to HER2-directed antibody therapy in breast cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content